ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

GreenLight Biosciences has received a €35 million loan from the European Investment Bank (EIB) to advance its RNA-based biocontrol products, of ...

Home > Press release: Research Training Group for the further ...

Despite the key role of messenger RNA in the translation of DNA into protein has been known since Crick described it in the late 50s, it hadn’t been investigated as a therapeutic product until much ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization ...

2018 saw a breakthrough in the field of RNA interference (RNAi), when the US FDA approved the first drug using this gene-silencing mechanism. Five years and five more approved drugs later ...

Biotium, proudly announces the release of EMBER™ Ultra Gel Kits for RNA and DNA gel electrophoresis. Both kits use a novel gel system of EMBER™ Ultra Precoated Agarose with EMBER™ Loading Dye to ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

RNAi (RNA interference) is a biological process in which RNA molecules—microRNA (miRNA) and small interfering RNA (siRNA)—inhibit gene expression, typically by binding to messenger RNA (mRNA ...

The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...